Hematopoietic Stem Cells (HSCs) are unique cell types that require specialized genome engineering techniques as well as specific handling and manipulation processes. We have built considerable know-how manipulating genes of these cells and have also designed a highly efficient manufacturing process for VOR33 of approximately three days.
We are investing in our know-how and manufacturing processes, including the build-out of our own in-house clinical manufacturing facility at our Cambridge, MA headquarters. The facility has been designed to support flexible clinical manufacturing for our eHSC and Chimeric Antigen Receptor T (CAR-T) product candidate pipeline and allow enhanced strategic control.